[HTML][HTML] European Association of Urology guidelines on renal cell carcinoma: the 2022 update

…, T Klatte, T Kuusk, TB Lam, L Marconi, T Powles… - European urology, 2022 - Elsevier
… Thomas Powles has received institutional research funding from AstraZeneca, Roche,
BMS, Exelixis, Ipsen, Merck/MSD, Novartis, Pfizer, Seattle Genetics, Merck Serono, Astellas, …

EAU guidelines on renal cell carcinoma: 2014 update

…, L Marconi, AS Merseburger, P Mulders, T Powles… - European urology, 2015 - Elsevier
… Thomas Powles has received grants or research support from GSK, Pfizer, Astellas, GSK,
Roche, Pfizer, and Novartis, and speaker honoraria from Novartis, Pfizer and GSK, has …

Overview of the main outcomes in breast-cancer prevention trials

J Cuzick, T Powles, U Veronesi, J Forbes, R Edwards… - The Lancet, 2003 - thelancet.com
Background Early findings on the use of tamoxifen or raloxifene as prophylaxis against breast
cancer have been mixed; we update available data and overview the combined results. …

[HTML][HTML] Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma

…, C Porta, S George, T Powles… - … England Journal of …, 2018 - Mass Medical Soc
Background Nivolumab plus ipilimumab produced objective responses in patients with
advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus …

[HTML][HTML] Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma

…, SY Rha, C Porta, M Eto, T Powles… - … England Journal of …, 2021 - Mass Medical Soc
Background Lenvatinib in combination with pembrolizumab or everolimus has activity against
advanced renal cell carcinoma. The efficacy of these regimens as compared with that of …

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a …

JE Rosenberg, J Hoffman-Censits, T Powles… - The Lancet, 2016 - thelancet.com
Background Patients with metastatic urothelial carcinoma have few treatment options after
failure of platinum-based chemotherapy. In this trial, we assessed treatment with atezolizumab…

[HTML][HTML] Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma

TK Choueiri, T Powles, M Burotto… - … England Journal of …, 2021 - Mass Medical Soc
Background The efficacy and safety of nivolumab plus cabozantinib as compared with those
of sunitinib in the treatment of previously untreated advanced renal-cell carcinoma are not …

[HTML][HTML] Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma

…, DI Quinn, T Powles - … England Journal of …, 2021 - Mass Medical Soc
Background Patients with renal-cell carcinoma who undergo nephrectomy have no options
for adjuvant therapy to reduce the risk of recurrence that have high levels of supporting …

[HTML][HTML] COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study

…, C Palles, Y Pan, R Pettengell, T Powles… - The Lancet, 2020 - thelancet.com
… The two-sided Welch's t test was used to compare continuous data and two-sided Fisher's
exact test was used to compare categorical data from different categories with multivariate …

The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial

…, D Grady, TJ Powles, JA Cauley, L Norton, T Nickelsen… - Jama, 1999 - jamanetwork.com
… total of 7705 postmenopausal women, younger than 81 (mean age, 66.5) years, with
osteoporosis, defined by the presence of vertebral fractures or a femoral neck or spine T-score of at …